Trials / Completed
CompletedNCT02159859
Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Corewell Health East · Academic / Other
- Sex
- All
- Age
- 18 Years – 88 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.
Detailed description
After a hemodialysis session, subject will be administered ertapenem and the amount of ertapenem in the blood will be measured at seven time periods before the initiation of the next hemodialysis session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ertapenem | Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-06-10
- Last updated
- 2018-10-17
- Results posted
- 2017-06-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02159859. Inclusion in this directory is not an endorsement.